Arbutus Biopharma Corp
ABUS4.780USD
-0.010-0.21%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
917.54MMarket Cap
LossP/E TTM
More Details of Arbutus Biopharma Corp Company
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease. The Company is developing imdusiran (AB-729), its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). Its HBV product pipeline includes Imdusiran and AB-101. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for. PD-L1 inhibitors complement its pipeline of agents and could potentially be a part of a combination therapy for the treatment of HBV by reawakening the immune system.
Arbutus Biopharma Corp Info
Ticker SymbolABUS
Company nameArbutus Biopharma Corp
IPO dateNov 13, 2010
CEOAndroski (Lindsay)
Number of employees44
Security typeOrdinary Share
Fiscal year-endNov 13
Address701 Veterans Circle
CityWARMINSTER
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code18974
Phone16044193200
Websitehttps://www.arbutusbio.com/
Ticker SymbolABUS
IPO dateNov 13, 2010
CEOAndroski (Lindsay)
Company Executives of Arbutus Biopharma Corp
Name
Name/Position
Position
Shareholding
Change
Mr. Joseph Bishop
Mr. Joseph Bishop
Independent Director
Independent Director
--
--
Mr. Matthew Gline
Mr. Matthew Gline
Independent Director
Independent Director
--
--
Mr. Robert Alan Beardsley
Mr. Robert Alan Beardsley
Independent Director
Independent Director
--
--
Ms. Lindsay Androski, J.D.
Ms. Lindsay Androski, J.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Dr. Roger Sawhney, M.D.
Dr. Roger Sawhney, M.D.
Independent Director
Independent Director
--
--
Mr. Tuan Nguyen
Mr. Tuan Nguyen
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Joseph Bishop
Mr. Joseph Bishop
Independent Director
Independent Director
--
--
Mr. Matthew Gline
Mr. Matthew Gline
Independent Director
Independent Director
--
--
Mr. Robert Alan Beardsley
Mr. Robert Alan Beardsley
Independent Director
Independent Director
--
--
Ms. Lindsay Androski, J.D.
Ms. Lindsay Androski, J.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Dr. Roger Sawhney, M.D.
Dr. Roger Sawhney, M.D.
Independent Director
Independent Director
--
--
Mr. Tuan Nguyen
Mr. Tuan Nguyen
Chief Financial Officer
Chief Financial Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Roivant Sciences Ltd.
20.20%
Morgan Stanley Investment Management Inc. (US)
12.12%
Whitefort Capital Management, LP
6.94%
BlackRock Institutional Trust Company, N.A.
5.86%
Two Seas Capital LP
5.71%
Other
49.16%
Shareholders
Shareholders
Proportion
Roivant Sciences Ltd.
20.20%
Morgan Stanley Investment Management Inc. (US)
12.12%
Whitefort Capital Management, LP
6.94%
BlackRock Institutional Trust Company, N.A.
5.86%
Two Seas Capital LP
5.71%
Other
49.16%
Shareholder Types
Shareholders
Proportion
Hedge Fund
23.84%
Corporation
20.20%
Investment Advisor/Hedge Fund
19.92%
Investment Advisor
15.25%
Research Firm
2.76%
Individual Investor
1.63%
Bank and Trust
0.63%
Pension Fund
0.17%
Insurance Company
0.03%
Other
15.57%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
303
120.46M
63.27%
+16.91K
2025Q3
308
120.41M
63.81%
+205.66K
2025Q2
303
120.18M
60.87%
+6.31M
2025Q1
305
113.89M
56.48%
+5.73M
2024Q4
291
105.12M
56.03%
+2.81M
2024Q3
289
102.16M
54.67%
+4.63M
2024Q2
265
97.30M
48.54%
+13.53M
2024Q1
263
83.76M
49.95%
-6.24M
2023Q4
266
79.35M
51.53%
+6.48M
2023Q3
271
71.63M
47.28%
+4.69M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Roivant Sciences Ltd.
38.85M
20.26%
--
--
Feb 25, 2025
Morgan Stanley Investment Management Inc. (US)
23.06M
12.03%
+365.18K
+1.61%
Jun 30, 2025
Whitefort Capital Management, LP
13.34M
6.96%
+35.26K
+0.26%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
11.47M
5.98%
+59.31K
+0.52%
Jun 30, 2025
Two Seas Capital LP
10.44M
5.45%
+977.36K
+10.33%
Jun 30, 2025
The Vanguard Group, Inc.
9.05M
4.72%
+131.26K
+1.47%
Jun 30, 2025
Adage Capital Management, L.P.
2.58M
1.34%
+1.00M
+63.45%
Jun 30, 2025
State Street Investment Management (US)
4.46M
2.33%
+96.25K
+2.21%
Jun 30, 2025
Geode Capital Management, L.L.C.
3.64M
1.9%
+95.88K
+2.71%
Jun 30, 2025
Adar1 Capital Management LLC
2.83M
1.47%
+946.66K
+50.38%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
0.89%
Invesco NASDAQ Future Gen 200 ETF
0.69%
Hypatia Women CEO ETF
0.28%
iShares Micro-Cap ETF
0.14%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.11%
ProShares Ultra Nasdaq Biotechnology
0.09%
Invesco Nasdaq Biotechnology ETF
0.08%
iShares ESG Aware MSCI USA Small-Cap ETF
0.07%
State Street SPDR S&P Biotech ETF
0.06%
iShares Biotechnology ETF
0.06%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.89%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.69%
Hypatia Women CEO ETF
Proportion0.28%
iShares Micro-Cap ETF
Proportion0.14%
iShares MSCI USA Small-Cap Min Vol Factor ETF
Proportion0.11%
ProShares Ultra Nasdaq Biotechnology
Proportion0.09%
Invesco Nasdaq Biotechnology ETF
Proportion0.08%
iShares ESG Aware MSCI USA Small-Cap ETF
Proportion0.07%
State Street SPDR S&P Biotech ETF
Proportion0.06%
iShares Biotechnology ETF
Proportion0.06%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Arbutus Biopharma Corp?
The top five shareholders of Arbutus Biopharma Corp are:
Roivant Sciences Ltd. holds 38.85M shares, accounting for 20.26% of the total shares.
Morgan Stanley Investment Management Inc. (US) holds 23.06M shares, accounting for 12.03% of the total shares.
Whitefort Capital Management, LP holds 13.34M shares, accounting for 6.96% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 11.47M shares, accounting for 5.98% of the total shares.
Two Seas Capital LP holds 10.44M shares, accounting for 5.45% of the total shares.
Roivant Sciences Ltd. holds 38.85M shares, accounting for 20.26% of the total shares.
Morgan Stanley Investment Management Inc. (US) holds 23.06M shares, accounting for 12.03% of the total shares.
Whitefort Capital Management, LP holds 13.34M shares, accounting for 6.96% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 11.47M shares, accounting for 5.98% of the total shares.
Two Seas Capital LP holds 10.44M shares, accounting for 5.45% of the total shares.
What are the top three shareholder types of Arbutus Biopharma Corp?
The top three shareholder types of Arbutus Biopharma Corp are:
Roivant Sciences Ltd.
Morgan Stanley Investment Management Inc. (US)
Whitefort Capital Management, LP
Roivant Sciences Ltd.
Morgan Stanley Investment Management Inc. (US)
Whitefort Capital Management, LP
How many institutions hold shares of Arbutus Biopharma Corp (ABUS)?
As of 2025Q4, 303 institutions hold shares of Arbutus Biopharma Corp, with a combined market value of approximately 120.46M, accounting for 63.27% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.55%.
What is the biggest source of revenue for Arbutus Biopharma Corp?
In --, the -- business generated the highest revenue for Arbutus Biopharma Corp, amounting to -- and accounting for --% of total revenue.
